Evidence map›Paper›PMID 26655167›Full record

ArticleMicrobial cell factories2015

Three-dimensional tumor spheroids for in vitro analysis of bacteria as gene delivery vectors in tumor therapy.

Annika Osswald, Zhongke Sun, Verena Grimm, Grace Ampem, Karin Riegel, Astrid M Westendorf, Wolfgang Sommergruber, Kerstin Otte, Peter Dürre, Christian U Riedel

Open access · goldAbstract read
In one paragraph

Article in Microbial cell factories, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers.

0numbers the graph read from it
0cells of the map it votes in
13citing papers in PubMed
2.3field-weighted citation impact, top 13% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

13 citing papers in PubMed, 26 citations in OpenAlex.

  1. Article
  2. EngineeredCancers · 2025
    Review
  3. Review
  4. Article
  5. Article
  6. Article
  7. Review
  8. Article
  9. Article
  10. Engineering bacteria for cancer therapy.Emerging topics in life sciences · 2019
    Article
  11. Rapid screening of engineered microbial therapies in a 3D multicellular model.Proceedings of the National Academy of Sciences of the United States of America · 2019
    Article
  12. Article
  13. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 4 institutions in 2 countries.

Annika OsswaldInstitute of Microbiology and Biotechnology, University of Ulm, 89069, Ulm, Germany. annika.osswald.ext@boehringer-ingelheim.com.
Zhongke SunInstitute of Microbiology and Biotechnology, University of Ulm, 89069, Ulm, Germany. szj008@126.com.
Verena GrimmInstitute of Microbiology and Biotechnology, University of Ulm, 89069, Ulm, Germany. verena.grimm@uni-ulm.de.
Grace AmpemInstitute of Microbiology and Biotechnology, University of Ulm, 89069, Ulm, Germany. grace.ampem@uni-ulm.de.
Karin RiegelInstitute of Microbiology and Biotechnology, University of Ulm, 89069, Ulm, Germany. karin.riedel@uni-ulm.de.
Astrid M WestendorfInstitute of Medical Microbiology, University Hospital Essen, University Duisburg-Essen, Essen, Germany. astrid.westendorf@uk-essen.de.
Wolfgang SommergruberDepartment of Lead Discovery, Boehringer Ingelheim RCV GmbH & Co KG, 1121, Vienna, Austria. wolfgang.sommergruber@boehringer-ingelheim.com.
Kerstin OtteInstitute of Applied Biotechnology, University of Applied Sciences Biberach, 88400, Biberach, Germany. otte@hochschule-bc.de.
Peter DürreInstitute of Microbiology and Biotechnology, University of Ulm, 89069, Ulm, Germany. peter.duerre@uni-ulm.de.
Christian U RiedelInstitute of Microbiology and Biotechnology, University of Ulm, 89069, Ulm, Germany. christian.riedel@uni-ulm.de.
Universität Ulm · DEBoehringer Ingelheim (Austria) · ATUniversity of Applied Sciences Biberach · DEUniversity of Duisburg-Essen · DE

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundSeveral studies in animal models demonstrated that obligate and facultative anaerobic bacteria of the genera Bifidobacterium, Salmonella, or Clostridium specifically colonize solid tumors. Consequently, these and other bacteria are discussed as live vectors to deliver therapeutic genes to inhibit tumor growth. Therapeutic approaches for cancer treatment using anaerobic bacteria have been investigated in different mouse models. In the present study, solid three-dimensional (3D) multicellular tumor spheroids (MCTS) of the colorectal adenocarcinoma cell line HT-29 were generated and tested for their potential to study prodrug-converting enzyme therapies using bacterial vectors in vitro.

resultsHT-29 MCTS resembled solid tumors displaying all relevant features with an outer zone of proliferating cells and hypoxic and apoptotic regions in the core. Upon incubation with HT-29 MCTS, Bifidobacterium bifidum S17 and Salmonella typhimurium YB1 selectively localized, survived and replicated in hypoxic areas inside MCTS. Furthermore, spores of the obligate anaerobe Clostridium sporogenes germinated in these hypoxic areas. To further evaluate the potential of MCTS to investigate therapeutic approaches using bacteria as gene delivery vectors, recombinant bifidobacteria expressing prodrug-converting enzymes were used. Expression of a secreted cytosine deaminase in combination with 5-fluorocytosine had no effect on growth of MCTS due to an intrinsic resistance of HT-29 cells to 5-fluorouracil, i.e. the converted drug. However, a combination of the prodrug CB1954 and a strain expressing a secreted chromate reductase effectively inhibited MCTS growth.

conclusionsCollectively, the presented results indicate that MCTS are a suitable and reliable model to investigate live bacteria as gene delivery vectors for cancer therapy in vitro.

Indexed as

AnimalsCell Line, TumorGenetic TherapyGenetic VectorsHumansIn Vitro TechniquesMiceSpheroids, Cellular

Identifiers

PMID26655167
PMCPMC4676896
OpenAlexW2195242704

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.